galcanezumab

Home
Ligands
galcanezumab

GtoPdb Ligand ID: 8967

Synonyms: clone III | Emgality® | galcanezumab-gnlm | LY-2951742 | LY2951742

galcanezumab is an approved drug (FDA (2018))

Comment: Galcanezumab (LY2951742) is a monoclonal antibody targeting calcitonin A and B (CALCA a.k.a. α-CGRP and CALCB a.k.a. β-CGRP respectively), whose anti-migraine and analgesic actions can be applied clinically.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent WO2007076336 [1].

References
1. Benschop RJ, Gehlert DR, Merchant KM, Shanafelt AB. (2007) Treatment of migraine with anti-CGRP antibodies. Patent number: WO2007076336 A1. Assignee: Eli Lilly Co., Benschop RJ, Gehlert DR, Merchant KM, Shanafelt AB. Priority date: 22/12/2005. Publication date: 05/07/2007.
2. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol, 13 (9): 885-92. [PMID:25127173]

References

1. Benschop RJ, Gehlert DR, Merchant KM, Shanafelt AB. (2007)
Treatment of migraine with anti-CGRP antibodies.
Patent number: WO2007076336 A1. Assignee: Eli Lilly Co., Benschop RJ, Gehlert DR, Merchant KM, Shanafelt AB. Priority date: 22/12/2005. Publication date: 05/07/2007.

2. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. (2014)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
Lancet Neurol, 13 (9): 885-92. [PMID:25127173]